Compile Data Set for Download or QSAR
Report error Found 231 Enz. Inhib. hit(s) with all data for entry = 9587
TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475984({(2R,3S,4R,5R)-5-[4-amino-3-(methylsulfanyl)-1H-py...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475982([(2R,3S,4R,5R)-5-{4-amino-3-[(3-chlorophenyl)sulfa...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476046({(2R,3R,4S,5R)-5-[4-amino-3-(cyclopentylsulfanyl)-...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476012([(2R,3S,4R,5R)-5-{4-amino-3-[(3-methylphenyl)sulfa...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475978({(2R,3S,4R,5R)-5-[4-amino-3-(1H-pyrazol-4-ylsulfan...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476008({(2R,3S,4R,5R)-5-[4-amino-3-(cyclopropylsulfanyl)-...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476005({(2R,3S,4R,5R)-5-[4-amino-3-(cyclopentylsulfanyl)-...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476001({(2R,3S,4R,5R)-5-[4-amino-3-(isopropylsulfanyl)-1H...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476097([(2R,3R,4S,5R)-5-{4-amino-3-[(5-methylpyridin-2-yl...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476032([(2R,3S,4R,5R)-5-{4-amino-3-[(4-methylphenyl)sulfa...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475999({(2R,3S,4R,5R)-5-[4-amino-3-(cyclobutylsulfanyl)-1...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476061({(2R,3R,4S,5R)-5-[4-amino-3-(tert-butylsulfanyl)-1...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476093([(2R,3R,4S,5R)-5-{4-amino-3-[(cyclobutylmethyl)sul...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476092({(2R,3R,4S,5R)-5-[4-amino-3-(cyclobutylsulfanyl)-1...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476057([(2R,3R,4S,5R)-5-{4-amino-3-[(4-methylpyridin-2-yl...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475992([(2R,3S,4R,5R)-5-{4-amino-3-[(cyclopropylmethyl)su...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476056({(2R,3R,4S,5R)-5-[4-amino-3-(pyridin-2-ylsulfanyl)...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476022([(2R,3S,4R,5R)-5-(4-amino-3-iodo-1H-pyrazolo[3,4-d...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475988([(2R,3S,4R,5R)-5-{4-amino-3-[(2-hydroxyethyl)sulfa...)
Affinity DataIC50: 20nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475983([(2R,3S,4R,5R)-5-{4-amino-3-[(4-methylbenzyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475981([(2R,3S,4R,5R)-5-{4-amino-3-[(2-methylbenzyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475980([(2R,3S,4R,5R)-5-{4-amino-3-[(4-methoxybenzyl)sulf...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475977([(2R,3S,4R,5R)-5-{4-amino-3-[(2-methoxyethyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475975([(2R,3S,4R,5R)-5-(4-amino-3-{[4-(trifluoromethyl)b...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475974([(2R,3S,4R,5R)-5-(4-amino-3-{[4-(trifluoromethoxy)...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476102([(2R,3R,4S,5R)-5-(4-amino-3-{[(1R)-1-cyclopropylet...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475973([(2R,3S,4R,5R)-5-{4-amino-3-[(3-methylbenzyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476100({(2R,3R,4S,5R)-5-[4-amino-3-(benzylsulfanyl)-1H-py...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475969({(2R,3S,4R,5R)-5-[4-amino-3-(difluoromethoxy)-1H-p...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476126({(2R,3S,5R)-5-[4-amino-3-(isopropylsulfanyl)-1H-py...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475996([(2R,3S,4R,5R)-5-(4-amino-3-{[(1R,2R)-2-hydroxycyc...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475995({(2R,3S,4R,5R)-5-[4-amino-3-(tert-butylsulfanyl)-1...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476123([(2R,3S,5R)-5-{4-amino-3-[(2-fluoro-4-methoxypheny...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475994({(2R,3S,4R,5R)-5-[4-amino-3-(benzylsulfanyl)-1H-py...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476122({(2R,3S,5R)-5-[4-amino-3-(tert-butylsulfanyl)-1H-p...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475993({(2R,3S,4R,5R)-5-[4-amino-3-(ethylsulfanyl)-1H-pyr...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476119({(2R,3S,5R)-5-[4-amino-3-(1,3-thiazol-2-ylsulfanyl...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476118([(2R,3S,5R)-5-{4-amino-3-[(2-fluoro-5-methoxypheny...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475987([(2R,3S,4R,5R)-5-{4-amino-3-[(pyridin-3-ylmethyl)s...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475986([(2R,3S,4R,5R)-5-{4-amino-3-[(3-fluorobenzyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM475985({(2R,3S,4R,5R)-5-[4-amino-3-(prop-2-yn-1-ylsulfany...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476113({(2R,3S,5R)-5-[4-amino-3-(2,3-dihydro-1-benzofuran...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476016([(2R,3S,4R,5R)-5-(4-amino-3-{[(5-chloro-2-furyl)me...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476144([(2R,3S,5R)-5-{4-amino-3-[(3-methoxyphenyl)sulfany...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476139({(2R,3S,5R)-5-[4-amino-3-(pyridin-2-ylsulfanyl)-1H...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476009({(2R,3S,4R,5R)-5-[4-amino-3-(pyridin-4-ylsulfanyl)...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476007([(2R,3S,4R,5R)-5-{4-amino-3-[(4-chlorophenyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476006([(2R,3S,4R,5R)-5-{4-amino-3-[(4-fluorobenzyl)sulfa...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476004([(2R,3S,4R,5R)-5-{4-amino-3-[(1-methyl-1H-pyrazol-...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

TargetUbiquitin-like modifier-activating enzyme ATG7(Human)
Millennium Pharmaceuticals

US Patent
LigandPNGBDBM476131({(2R,3S,5R)-5-[4-amino-3-(2,3-dihydro-1-benzofuran...)
Affinity DataIC50: 35nMAssay Description:The total volume of the ATG7 enzymatic assay is 50 μL and contains 50 mM HEPES Hemisodium (pH 7.5), 0.05% BSA, 0.01% Tween-20, 25 mM NaCl, 5 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
US Patent

Displayed 1 to 50 (of 231 total ) | Next | Last >>
Jump to: